Bionano Genomics, Inc. (BNGO) |
| 1.2436 -0.006 (-0.51%) 05-29 15:05 |
| Open: | 1.25 |
| High: | 1.27 |
| Low: | 1.22 |
| Volume: | 159,248 |
| Market Cap: | 4(M) |
| PE Ratio: | -0.28 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.38 |
| Resistance 1: | 1.29 |
| Pivot price: | 1.23 |
| Support 1: | 1.13 |
| Support 2: | 0.94 |
| 52w High: | 5.5 |
| 52w Low: | 1.06 |
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
| EPS | -4.850 |
| Book Value | 3.320 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.217 |
| Profit Margin (%) | -109.94 |
| Operating Margin (%) | -118.10 |
| Return on Assets (ttm) | -28.6 |
| Return on Equity (ttm) | -73.8 |
Thu, 28 May 2026
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors - Yahoo Finance
Thu, 28 May 2026
Bionano Genomics (NASDAQ: BNGO) eliminates $20M secured debt load - Stock Titan
Wed, 27 May 2026
BNGO Stock Price, Quote & Chart | BIONANO GENOMICS INC (NASDAQ:BNGO) - ChartMill
Fri, 22 May 2026
BNGO News | BIONANO GENOMICS INC (NASDAQ:BNGO) - ChartMill
Sat, 16 May 2026
Bionano Genomics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:BNGO) 2026-05-16 - Seeking Alpha
Fri, 15 May 2026
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2026 Earnings Call Transcript - Insider Monkey
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |